- Home
- CABO vs CNTA Comparison
CABO vs CNTA Comparison
Compare CABO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABO | CNTA |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 6.1B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CABO | CNTA |
|---|---|---|
| Price | $50.37 | $39.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $125.67 | $43.17 |
| AVG Volume (30 Days) | 150.5K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $1,501,423,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $9.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.94 | $10.95 |
| 52 Week High | $180.74 | $40.26 |
Technical Indicators
Market Signals| Indicator | CABO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 25.07 | 72.11 |
| Support Level | N/A | $39.36 |
| Resistance Level | $117.15 | $39.86 |
| Average True Range (ATR) | 9.08 | 0.15 |
| MACD | -4.38 | -0.39 |
| Stochastic Oscillator | 0.97 | 47.52 |
Price Performance
Historical ComparisonAbout CABO Cable One Inc.
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.